Inflammatory factors, adipocytokines, and the metabolic syndrome are important determinants of cardiometabolic disease. It remains unknown whether physical activity, a key modifiable factor for cardiometabolic disease control and prevention, may modify these cardiovascular risk factors. We analyzed single and joint associations of physical activity, inflammatory factors, adipocytokines, and the metabolic syndrome among 3289 Chinese people 50 to 70 years of age who participated in a cross-sectional survey in Beijing and Shanghai in 2005. Levels of total physical activity were assessed with the International Physical Activity Questionnaire. Inflammatory factors (high-sensitivity C-reactive protein, interleukin-6, and tumor necrosis factor-␣ receptor 2) and adipocytokines (adiponectin and retinol-binding protein 4) were measured. The metabolic syndrome was defined according to the National Cholesterol Education Program/Adult Treatment Panel III criteria for Asian Americans. In multivariable regression analyses, high levels of total physical activity were significantly associated with a 20% lower level of high-sensitivity C-reactive protein, 7% higher level of adiponectin, and 30% lower risk of having the metabolic syndrome compared with those with low levels. Importantly, higher levels of physical activity were associated with a lower likelihood of having the metabolic syndrome even among individuals with adverse levels of inflammatory factors or adipocytokines. Even moderate-intensity activities were related to the health benefits. Public health recommendations to promote moderate-to vigorous-intensity activities may help to curtail the current epidemic of cardiometabolic disorders in Chinese people.
There is concern that performance measures, patient ratings of their care, and pay-for-performance programs may penalize healthcare providers of patients with multiple chronic coexisting conditions. We classified 141 609 veterans with hypertension into 4 condition groups: those with hypertension-concordant (diabetes mellitus, ischemic heart disease, dyslipidemia) and/or -discordant (arthritis, depression, chronic obstructive pulmonary disease) conditions or neither. We measured blood pressure control at the index visit, overall good quality of care for hypertension, including a follow-up interval, and patient ratings of satisfaction with their care. Associations between condition type and number of coexisting conditions on receipt of overall good quality of care were assessed with logistic regression. Odds of receiving overall good quality after adjustment for age were higher for those with concordant comorbidities (odds ratio, 1.78; 95% confidence interval, 1.70 to 1.87), discordant comorbidities (odds ratio, 1.32; 95% confidence interval, 1.23 to 1.41), or both (odds ratio, 2.25; 95% confidence interval, 2.13 to 2.38) compared with neither. Findings did not change after adjustment for illness severity and/or number of primary care and specialty care visits. Patient assessment of quality did not vary by the presence of coexisting conditions and was not related to objective ratings of quality of care. Therefore, contrary to expectations, patients with greater complexity had higher odds of receiving high-quality care. Subjective ratings of care did not vary with the presence or absence of comorbid conditions. Our findings should be reassuring to those who care for the most medically complex patients and are concerned that they will be penalized by performance measures or patient ratings of their care. See p 2978.
Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Coated Stent for the Treatment of Coronary In-Stent Restenosis
Drug-eluting stents are currently considered the best possible care in the treatment of in-stent restenosis. However, they include the presence of 2 layers of metal and may further reduce the flexibility of the vessel and limit the repeatability of the procedure. First-inhuman trials with short-time local drug delivery using a paclitaxelcoated balloon catheter as compared with plain balloon angioplasty have shown beneficial effects in the treatment of coronary in-stent restenosis and in peripheral arteries. The PEPCAD (PaclitaxelEluting PTCA-Balloon Catheter in Coronary Artery Disease) II trial compares the drug-coated SeQuent Please balloon with the approved and recognized drug-eluting Taxus Liberté stent. Angiographic late lumen loss was significantly lower with the coated balloon as compared with the drug-eluting stent. Furthermore, there was a trend toward a reduction of clinical events. Treatment of coronary in-stent restenosis with the paclitaxel-coated balloon was at least as efficacious and as well tolerated as the paclitaxel-eluting stent. For the treatment of in-stent restenosis, inhibition of re-restenosis does not require a second stent implantation. See p 2986.
Comparison of Bare Metal Stenting and Percutaneous Pulmonary Valve Implantation for Treatment of Right Ventricular Outflow Tract Obstruction: Use of an X-Ray/Magnetic Resonance Hybrid Laboratory for Acute Physiological Assessment
In this study, we assessed children undergoing sequential bare metal stenting and percutaneous pulmonary valve implantation in the setting of an x-ray/magnetic resonance hybrid laboratory to compare the acute physiological consequences for biventricular function. Bare metal stenting has been proposed as a treatment option to prolong the lifespan of conduits and has been the gold standard for nonsurgical treatment of conduit obstruction over the last few decades. However, relief of obstruction comes at the expense of pulmonary incompetence. Recently, percutaneous pulmonary valve implantation has become a reality. This technique allows successful relief of conduit obstruction without causing valvar incompetence. Although a comparison of pressure measurements in our study showed similar beneficial effects of bare metal stenting and percutaneous pulmonary valve implantation (reduced right ventricular outflow tract gradient, reduced right ventricular pressures), combined assessment of both catheter and magnetic resonance data revealed that biventricular effective stroke volumes improve only after percutaneous pulmonary valve implantation. Therefore, at least acutely, percutaneous pulmonary valve implantation is superior to bare metal stenting in improving biventricular efficiency and should therefore represent the first nonsurgical treatment option in patients with conduit obstruction. This study also shows a novel utility of an x-ray/magnetic resonance hybrid laboratory to assess physiological changes after interventions more comprehensively. The results of this study emphasize the importance of assessing not only pressures but also 
Impact of Percutaneous Device Implantation for Closure of Patent Foramen Ovale on Valve Insufficiencies
There is an increasing use of percutaneous transcatheter device implantation for closure of patent foramen ovale (PFO). Recently with sequential echocardiography, a 10% incidence of new or worsened aortic regurgitation within a 12-month period was reported. Although echocardiography is the currently preferred approach for detection of valve insufficiencies, quantification of regurgitation is more accurate with cardiac magnetic resonance imaging. We studied the acute and long-term impact of percutaneous device implantation for PFO closure on valve insufficiencies with sequential cardiac magnetic resonance imaging in 102 patients with cryptogenic ischemic events. Cardiac magnetic resonance imaging was performed before PFO closure, the day after device implantation, and at 12 months of follow-up. There was no difference in volumetric and hemodynamic parameters before PFO closure compared with 12 months of follow-up. With a cutoff for relevant regurgitation fraction of 5%, there were no statistically significant differences in regurgitation fraction of the semilunar and atrioventricular valves. The median fraction of aortic valve insufficiency was 3.9% (interquartile range 2.0% to 5.1%) before PFO closure, 5.4% (interquartile range 4.1% to 5.9%) after device implantation, and 4.3% (interquartile range 3.3% to 6.0%) at 12 months. In addition, the size (Յ or Ͼ25 mm) and type of the occluder (Cardia or Amplatzer) had no impact on aortic valve insufficiency. A systemic left-to-right shunt was seen in 24 of 102 patients (23.5%) before intervention, persisting in 6 patients after occluder implantation, which disappeared until 12 months of follow-up. We were able to demonstrate that percutaneous PFO closure with device implantation has no impact on valve insufficiencies as determined by cardiac magnetic resonance imaging. See p 3002.
Transcatheter Aortic Valve Implantation: Impact on Clinical and Valve-Related Outcomes
Transcatheter aortic valve implantation was performed in 168 patients with severe aortic stenosis and high surgical risk in this transarterial (nϭ113) and off-pump transapical (nϭ55) single-center experience. Intraprocedural mortality was 1.2%. Operative (30-day) mortality was 11.3%, lower in the transarterial group than the transapical group (8.0% versus 18.2%). Mortality fell from the initial half to the second half of this experience, from 12.3% to 3.6% in transarterial patients and from 25% to 11.1% in transapical patients. There was early and sustained functional improvement. At a maximum of Ͼ3 years and a median of 221 days, structural valve failure was not observed. Paravalvular regurgitation was common but generally mild and remained stable at late follow-up. The bulk of late readmission and mortality was not procedure or valve related but rather due to comorbidities. Late outcome after transcatheter aortic valve implantation for aortic stenosis is determined primarily by comorbidities unrelated to aortic valve disease. See p 3009.
Heme Oxygenase 1 Determines Atherosclerotic Lesion Progression Into a Vulnerable Plaque
Sudden rupture of vulnerable atherosclerotic lesions at critical sites in the vasculature accounts for the high incidence of myocardial infarction and stroke in patients suffering from carotid artery disease. In this article, intraplaque heme oxygenase 1 levels were closely associated with increased plaque vulnerability in human carotid endarterectomy material. In addition, pharmaceutically and genetically introduced alterations in heme oxygenase 1 levels in a murine model of vulnerable plaque determined lesion outcome by affecting plaque stability. These present findings suggest that novel therapies based on increasing heme oxygenase 1 levels in patients with carotid artery disease could benefit patient outcome by stabilizing the plaque phenotype. See p 3017.
